On 26 February 2019, orphan designation (EU/3/19/2143) was granted by the European Commission to Pharma Mar S.A., Spain, for lurbinectedin for the treatment of small cell lung cancer.
Treatment of small cell lung cancer
|Date of designation||
|Orphan designation status||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: